1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
FreeCast sold 4,666,667 shares of Class A common stock and pre-funded warrants for 3,243,807 shares at $3.00 each in a private placement that closed July 2, 2026, for approximately $23.7 million in gross proceeds. The company plans to use the net proceeds for working capital and general corporate purposes and agreed to register the resale of the securities, which adds to the number of shares that could trade and dilutes existing holders.
Sold 4,666,667 shares of Class A common stock plus pre-funded warrants for 3,243,807 shares, priced at $3.00 per share or warrant
Gross proceeds of approximately $23.7 million before placement agent fees and expenses; closed July 2, 2026
Placement agent A.G.P./Alliance Global Partners was paid a cash fee of 5.0% on sales to new investors and 1.0% on sales to existing investors
Company must file a resale registration statement no later than the 12th trading day after the Registration Rights Agreement date
On June 30, 2026, Creative Medical Technology Holdings agreed with warrant holders to exercise existing warrants for 2,790,340 shares at a reduced price of $1.60 per share, down from $2.86, for gross proceeds of about $4.5 million before advisory fees. In exchange, the company issued new warrants for 5,580,680 shares at $1.60, which cannot be exercised until stockholder approval is obtained, so the transaction adds both cash and potential future share issuance for shareholders.
Existing warrants for 2,790,340 shares were exercised at $1.60 per share, reduced from $2.86, for about $4.5 million in gross proceeds before advisory fees.
New Inducement Warrants cover 5,580,680 shares at $1.60 and are exercisable for five years after Nasdaq-required stockholder approval.
Roth Capital Partners, LLC receives a fee of 8% of gross proceeds plus $50,000 in reimbursed legal expenses.
On July 1, 2026, the Compensation Committee approved a $100,000 bonus for CEO Timothy Warbington.
DNA X agreed on June 29, 2026 to sell 1,346,531 shares of non-voting Series B Convertible Preferred Stock to DNA Holdings Venture, Inc., a holder of more than 5% of its stock and an entity associated with director Scott Walker, for $8.1 million. The price is $6.00 per share, paid with $5.0 million in cash and the cancellation of $3.1 million of a convertible note issued in May 2026. The preferred stock converts into common stock after stockholder approval, so the deal can add shares outstanding and dilute existing holders.
1,346,531 Series B preferred shares at $6.00 per share, for an aggregate $8.1 million, including $5.0 million cash and $3.1 million of note balance cancelled
Preferred stock converts to common stock on the first trading day after stockholder approval; it is not convertible before that approval
Company expects to enter a consulting agreement at closing with DNA Holdings, Scott Walker and Brock Pierce for an aggregate 2,494,000 common shares, subject to stockholder approval
Company agreed to file a resale registration statement within 30 calendar days after stockholder approval, and DNA Holdings gets participation rights in future financings for twelve months
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.